Bausch Health Cos Inc. (NYSE:BHC) Stock Rated “Hold” by Sell-Side Brokerages

Shares of Bausch Health Cos Inc. (NYSE:BHC) have earned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $8.00.

Several research firms have recently commented on BHC. Zacks Research raised Bausch Health Cos from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 21st. Wall Street Zen upgraded shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Weiss Ratings upgraded Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and set a $9.00 target price on shares of Bausch Health Cos in a research report on Thursday, October 8th.

Insider Buying and Selling at Bausch Health Cos

In other Bausch Health Cos news, insider Aimee Lenar sold 36,827 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total transaction of $258,893.81. Following the completion of the transaction, the insider owned 334,853 shares in the company, valued at $2,354,016.59. This trade represents a 9.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bausch Health Cos

Several institutional investors have recently bought and sold shares of the business. Paulson & CO. Inc. purchased a new position in shares of Bausch Health Cos in the 2nd quarter valued at $361,151,000. MFN Partners Management LP bought a new position in shares of Bausch Health Cos during the 2nd quarter worth approximately $29,580,000. Royal Bank of Canada raised its stake in shares of Bausch Health Cos by 24.9% during the 1st quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock worth $61,362,000 after acquiring an additional 2,262,894 shares in the last quarter. Man Group plc acquired a new stake in Bausch Health Cos in the second quarter valued at approximately $7,157,000. Finally, Bank of America Corp DE acquired a new position in shares of Bausch Health Cos during the second quarter worth $2,816,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Price Performance

NYSE BHC opened at $6.33 on Tuesday. The stock has a market capitalization of $2.37 billion, a price-to-earnings ratio of -2.14 and a beta of 0.37. Bausch Health Cos has a 1-year low of $4.33 and a 1-year high of $8.00. The business’s fifty day moving average price is $6.17 and its 200-day moving average price is $5.61.

Bausch Health Cos (NYSE:BHC) last announced its earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.30. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. The business had revenue of $2.83 billion for the quarter, compared to analysts’ expectations of $2.59 billion. Equities research analysts anticipate that Bausch Health Cos will post 4.35 EPS for the current year.

Bausch Health Cos Company Profile

Bausch Health Companies Inc is a multinational specialty pharmaceutical company headquartered in Laval, Quebec. The company develops, manufactures and markets prescription medicines, branded and generic pharmaceuticals, over-the-counter products and medical devices across a range of therapeutic areas.

Its business includes Salix Pharmaceuticals, which focuses on gastrointestinal treatments; Ortho Dermatologics, which develops prescription therapies for dermatological conditions; and Solta Medical, which provides energy-based medical and aesthetic devices.